Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 15c
May 10, 2016 9:28 AM EDTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
... More